peptide therapy FAQ

Do not purchase. Peptides without third-party purity verification have unknown composition. You cannot validate experimental results using compounds of uncertain identity. Request batch-matched HPLC-MS documentation before ordering. If the supplier cannot provide independent lab verification for the specific batch you're receiving, the peptide is unsuitable for research that requires reproducibility. We've reviewed dozens of failed protocols traced to unverified peptide sourcing. The cost of wasted research time exceeds any savings from cheaper suppliers.

Many clinics offer telehealth peptide therapy with online consultations and nationwide shipping, so you can start treatment even if there's no in-person clinic nearby. Browse our telehealth peptide clinics to see providers that treat patients remotely.

Don't. Administer on an empty stomach at least 2–3 hours after eating. Elevated blood glucose and insulin both stimulate somatostatin release, which directly inhibits the GHRH receptor signaling pathway that drives sermorelin gene expression. Postprandial somatostatin tone can reduce GH response by 50–70% compared to fasting administration. The peptide still binds to receptors, but the downstream cAMP accumulation is blunted, limiting CREB phosphorylation and reducing transcriptional activation of the GH1 gene.

Discard the vial if reconstituted KPV was stored above 8°C for more than 4–6 hours. Peptide denaturation is irreversible and cannot be detected visually. Reconstituted peptides are temperature-sensitive biological molecules; extended exposure to room temperature causes the amino acid backbone to lose its tertiary structure, eliminating biological activity. Lyophilised (freeze-dried) KPV can tolerate short-term ambient temperature (up to 25°C for 24–48 hours) before reconstitution, but once mixed with bacteriostatic water, strict refrigeration at 2–8°C is non-negotiable.

KPV for IBS works best for inflammation-driven symptoms, which are more common in IBS-D (diarrhea-predominant) than IBS-C. If your constipation is linked to slow motility rather than intestinal inflammation, KPV's anti-inflammatory mechanism may not address the root cause. However, if faecal calprotectin is elevated or you have documented mucosal inflammation contributing to constipation (tight junctions disrupted, gut lining inflamed), KPV could reduce symptom burden by allowing the epithelium to repair. Request faecal calprotectin testing before starting. Levels above 50 mcg/g suggest inflammation that KPV can target.

Verify injection technique first. Subcutaneous administration should target abdominal or thigh tissue with proper needle depth (typically 5–8mm for a 0.5-inch insulin syringe). If technique is correct, consider receptor saturation or somatostatin interference. Doses above 1–2 mcg/kg don't produce proportionally higher GH responses because GHRH receptors saturate. Alternatively, if you've eaten recently or have elevated cortisol (stress, illness, poor sleep), somatostatin tone may be suppressing the response. Retesting under fasting conditions with proper sleep the night before provides a clearer assessment.

Combining sermorelin with a ghrelin mimetic like GHRP-2 or ipamorelin produces synergistic effects on sermorelin gene expression because the two pathways converge on the same somatotroph but through different receptor mechanisms. GHRH receptor activation increases cAMP; ghrelin receptor activation increases intracellular calcium and activates phospholipase C. Together, they amplify transcriptional machinery activation beyond what either peptide achieves alone. Standard combination protocols use equal doses of each peptide (e.g., 200 mcg sermorelin + 200 mcg GHRP-2) administered simultaneously before bed.

Continue the protocol for at least 4–6 weeks before concluding it's ineffective. Subcutaneous KPV typically shows initial symptom reduction within 10–14 days, but oral formulations require 3–4 weeks due to lower bioavailability and slower accumulation at the gut lining. If you're using oral KPV and see no change by week four, consider switching to subcutaneous administration or verifying that your oral capsules are enteric-coated. Uncoated oral KPV loses most of its potency in stomach acid, rendering the peptide functionally inactive before it reaches the intestine.

Verify peptide stability first. If the formulation wasn't stored properly or exceeds its reconstitution date, degraded peptide loses activity. Contact the compounding source to confirm batch potency and storage conditions. Two weeks represents the minimum timeframe for visible symptom change. Cytokine suppression occurs within days, but tissue remodeling and inflammation resolution require 3–4 weeks. If the underlying trigger remains active (ongoing microbial colonization, continued mechanical trauma), KPV will reduce inflammation but won't eliminate the condition. Add appropriate antimicrobial treatment or identify environmental triggers before concluding KPV ineffectiveness.

Cytokine levels rebound within 48–72 hours of stopping KPV. Missing 3–4 days resets progress. Inflammation may return to baseline before resuming treatment. Resume twice-daily application immediately and expect a 7–10 day lag before regaining symptom control. Consistent dosing matters more than high-dose intermittent application. Twice-daily low-dose KPV maintains receptor occupancy better than sporadic high-concentration use.

Irritation typically stems from the carrier vehicle. Not the peptide itself. DMSO-based formulations cause stinging and temporary redness in 30–40% of users, especially on inflamed or broken skin. Switch to a liposomal or emulsion-based carrier without alcohol or DMSO. If irritation persists with multiple formulations, consider subcutaneous administration instead. Injection-site discomfort resolves within 24 hours, whereas topical irritation can compound existing scalp sensitivity.

Discard it. A single 8–12 hour ambient temperature exposure (20–25°C) degrades approximately 15–25% of peptide potency, and there's no reliable field test to measure remaining bioavailability. Injecting degraded peptide doesn't cause harm, but it introduces uncontrolled variables into your research data. You're dosing an unknown concentration, which makes results uninterpretable. If the vial was out for fewer than 2 hours and the room temperature was below 22°C, refrigerate it immediately and use it within 7 days, noting the storage deviation in your research log for downstream analysis.

Resume at the standard dose. Do not double-dose to compensate. CJC-1295's extended half-life means plasma levels decline gradually, so missing 3 days won't drop you to baseline. Ipamorelin's short half-life means pulsatile stimulation stops immediately, but the cumulative IGF-1 elevation built over prior weeks persists for 7–10 days. The primary effect of a 3-day gap is loss of the acute nocturnal GH pulse, not collapse of long-term anabolic signaling. Resume evening dosing and continue the protocol without extending the study duration.

Do not inject. Properly reconstituted CJC Ipa Blend should be clear and colorless. Cloudiness indicates aggregation of denatured peptide fragments or bacterial contamination. Particulates suggest incomplete dissolution (which resolves with gentle swirling, not shaking) or stopper debris from improper needle insertion. If swirling doesn't clear the solution within 30 seconds, discard the vial. Aggregated peptides lose receptor binding affinity and can trigger immune responses in research models, compromising study endpoints.

Contact the supplier immediately and request a replacement or temperature log verification. Lyophilised peptides can tolerate brief temperature excursions (up to 30°C for 24–48 hours) with minimal degradation, but prolonged exposure above 35°C denatures the protein irreversibly. If gel packs are still cold or cool to the touch, the peptide is likely intact. If gel packs are warm and the package sat in a hot mailbox for hours, potency is compromised. Reputable suppliers like Real Peptides include temperature indicators or offer expedited cold-chain shipping during warm months to prevent this scenario.

Is peptide therapy safe? When administered by qualified professionals and sourced from reputable suppliers, peptide therapy is considered safe and effective for most individuals. How long does it take to see results? Results vary by peptide and individual goals. Some users notice improvements in energy, recovery, or skin health within weeks, while metabolic or disease-related benefits may take longer. Can peptides be taken orally? Traditionally, peptides required injection due to rapid degradation in the digestive tract. However, new delivery platforms are enabling stable oral formulations for select peptides. Are peptides legal? FDA regulations restrict the compounding and sale of certain peptides. Always consult a healthcare provider and verify the legal status before starting therapy. Where can I learn more or purchase research-grade peptides? For authoritative information and high-quality research peptides, visit Pure Tested Peptides.